These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. AIP and its interacting partners. Trivellin G; Korbonits M J Endocrinol; 2011 Aug; 210(2):137-55. PubMed ID: 21454441 [TBL] [Abstract][Full Text] [Related]
47. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Preda V; Korbonits M; Cudlip S; Karavitaki N; Grossman AB Eur J Endocrinol; 2014 Nov; 171(5):659-66. PubMed ID: 25184284 [TBL] [Abstract][Full Text] [Related]
48. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Occhi G; Trivellin G; Ceccato F; De Lazzari P; Giorgi G; Demattè S; Grimaldi F; Castello R; Davì MV; Arnaldi G; Salviati L; Opocher G; Mantero F; Scaroni C Eur J Endocrinol; 2010 Sep; 163(3):369-76. PubMed ID: 20530095 [TBL] [Abstract][Full Text] [Related]
49. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Ozkaya HM; Comunoglu N; Sayitoglu M; Keskin FE; Firtina S; Khodzhaev K; Apaydin T; Gazioglu N; Tanriover N; Oz B; Kadioglu P Pituitary; 2018 Aug; 21(4):335-346. PubMed ID: 29455389 [TBL] [Abstract][Full Text] [Related]
50. AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Lecoq AL; Viengchareun S; Hage M; Bouligand J; Young J; Boutron A; Zizzari P; Lombès M; Chanson P; Kamenický P Endocr Relat Cancer; 2016 May; 23(5):433-43. PubMed ID: 27080473 [TBL] [Abstract][Full Text] [Related]
51. Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. Pekkinen M; Ahlström MEB; Riehle U; Huttunen MM; Lamberg-Allardt CJE Bone; 2008 Jul; 43(1):84-91. PubMed ID: 18420479 [TBL] [Abstract][Full Text] [Related]
52. Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation. Williams F; Hunter S; Bradley L; Chahal HS; Storr HL; Akker SA; Kumar AV; Orme SM; Evanson J; Abid N; Morrison PJ; Korbonits M; Atkinson AB J Clin Endocrinol Metab; 2014 Apr; 99(4):1122-31. PubMed ID: 24423289 [TBL] [Abstract][Full Text] [Related]
53. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. Ramírez-Rentería C; Hernández-Ramírez LC; Portocarrero-Ortiz L; Vargas G; Melgar V; Espinosa E; Espinosa-de-Los-Monteros AL; Sosa E; González B; Zúñiga S; Unterländer M; Burger J; Stals K; Bussell AM; Ellard S; Dang M; Iacovazzo D; Kapur S; Gabrovska P; Radian S; Roncaroli F; Korbonits M; Mercado M Endocrine; 2016 Aug; 53(2):402-11. PubMed ID: 27033541 [TBL] [Abstract][Full Text] [Related]
54. Study of major genetic factors involved in pituitary tumorigenesis and their impact on clinical and biological characteristics of sporadic somatotropinomas and non-functioning pituitary adenomas. Foltran RK; Amorim PVGH; Duarte FH; Grande IPP; Freire ACTB; Frassetto FP; Dettoni JB; Alves VA; Castro I; Trarbach EB; Bronstein MD; Jallad RS Braz J Med Biol Res; 2018 Jun; 51(9):e7427. PubMed ID: 29947650 [TBL] [Abstract][Full Text] [Related]
55. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition. Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992 [TBL] [Abstract][Full Text] [Related]
56. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system. Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794 [TBL] [Abstract][Full Text] [Related]
57. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Houslay MD; Adams DR Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918 [TBL] [Abstract][Full Text] [Related]
58. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457 [TBL] [Abstract][Full Text] [Related]
59. Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Daly AF; Beckers A Endocrinol Metab Clin North Am; 2015 Mar; 44(1):19-25. PubMed ID: 25732638 [TBL] [Abstract][Full Text] [Related]
60. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Georgitsi M; Karhu A; Winqvist R; Visakorpi T; Waltering K; Vahteristo P; Launonen V; Aaltonen LA Br J Cancer; 2007 Jan; 96(2):352-6. PubMed ID: 17242703 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]